Technology evaluation: pegaptanib, Eyetech/Pfizer
Vinores, S.A.
Current Opinion in Molecular Therapeutics 5(6): 673-679
2003
ISSN/ISBN: 1464-8431 PMID: 14755895 Document Number: 559041
Eyetech Pharmaceuticals and Pfizer are co-developing the anti-vascular endothelial growth factor aptamer, pegaptanib, as an angiogenesis inhibitor for the potential treatment of age-related macular degeneration and diabetic macular edema, in addition to other ocular diseases. Gilead was previously investigating the aptamer for the potential treatment of cancer, however, no data have been published for this indication since 1999.